Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (121,176)		$ (99,916)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,269		10,648
Non-cash interest on 2033 Senior Notes	4,596		4,250
Amortization of deferred financing costs	1,907		993
Losses from investments in investees	2,486		7,861
Equity-based compensation – employees and non-employees	10,088		7,411
(Recovery of) provision for bad debts	(20)		810
Provision for inventory obsolescence	773		1,529
Revenue from receipt of equity	(180)		(12,680)
Realized gain on sale of equity securities	(1,273)		(10,953)
Gain on conversion of 3.00% convertible senior notes	(2,668)		(972)
Loss on sale of property, plant and equipment	0		56
Change in fair value of derivative instruments	(3,758)		48,351
In-process research and development	10,055		0
Change in fair value of contingent consideration	24,078		4,173
Deferred income tax benefit	0		(197)
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable	(4,140)		(724)
Inventory	(1,099)		952
Prepaid expenses and other current assets	3,487		(2,081)
Other assets	4,465		525
Accounts payable	(3,850)		2,303
Foreign currency measurement	1,008		(1,409)
Accrued expenses	(1,666)		9,467
Net cash used in operating activities	(65,618)		(29,603)
Cash flows from investing activities:
Investments in investees	(589)		(13,341)
Proceeds from sale of equity securities	1,331		11,628
Acquisition of businesses, net of cash	(1,683)		20,528
Purchase of marketable securities	0		(50,027)
Maturities of short-term marketable securities	0		25,016
Proceeds from the sale of property, plant and equipment	0		631
Capital expenditures	(3,935)		(2,991)
Net cash used in investing activities	(4,876)		(8,556)
Cash flows from financing activities:
Issuance of 2033 Senior Notes, net, including related parties	0		170,184
Payment of Series D dividends, including related parties	0		(3,015)
Proceeds from the exercise of Common Stock options and warrants	12,066		5,061
Contingent consideration payments	(6,435)		(2,539)
Borrowings on lines of credit	19,326		24,613
Repayments of lines of credit	(21,823)		(27,706)
Net cash provided by financing activities	3,134		166,598
Effect of exchange rate on cash and cash equivalents	(180)		34
Net (decrease) increase in cash and cash equivalents	(67,540)		128,473
Cash and cash equivalents at beginning of period	185,798	[1]	27,361
Cash and cash equivalents at end of period	118,258	[1]	155,834
SUPPLEMENTAL INFORMATION:
Interest paid	5,222		3,126
Income taxes paid, net	566		316
RXi common stock received	0		12,500
Pharmsynthez common stock received	6,264		0
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise	3,494		815
OPKO Biologics
Issuance of Common Stock to acquire:
Stock Issued	0		586,643
OPKO Renal
Issuance of Common Stock to acquire:
Stock Issued	21,155		146,902
OPKO Brazil
Issuance of Common Stock to acquire:
Stock Issued	0		436
OPKO Health Europe
Issuance of Common Stock to acquire:
Stock Issued	0		4,404
Arama Uruguay
Issuance of Common Stock to acquire:
Stock Issued	159		0
Inspiro
Issuance of Common Stock to acquire:
Stock Issued	8,566		0
Conversion of Series D Preferred Stock
Non-cash financing:
Series D Preferred Stock	0		24,386
Conversion of Senior Notes
Non-cash financing:
Series D Preferred Stock	$ 95,665		$ 20,839

[1] As of September 30, 2014 and December 31, 2013, total assets include $7.4 million and $6.7 million, respectively, and total liabilities include $13.1 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.